RudaCure (PDG Yongho Kim), une entreprise spécialisée dans le développement de traitements pour les troubles sensoriels, a été sélectionnée comme an Incheon Outstanding Company (Promising Enterprise) at the '2025 Incheon SME Awards and Outstanding Enterprise Certification Ceremony' hosted by Ville métropolitaine d'Incheon and organized by Incheon Technopark on the 12th, solidifying its position as a growing company in the bio-pharmaceutique development sector.
Founded in 2018, RudaCure has been dedicated to developing innovant drugs that directly and indirectly modulate the TRPV1 (Transient Receptor Potential Vanilloid 1) canal ionique, offering new treatment options for patients suffering from troubles sensoriels tels que sécheresse oculaire and douleur chronique.
RudaCure's core technology is a novel plateforme de médicaments that directly and indirectly modulates the TRPV1 canal ionique, which regulates pain, inflammation, and temperature sensation. TRPV1 is expressed in sensory nerves and plays a crucial role in transmission des signaux de douleur and réponses inflammatoires. By effectively modulating this channel, RudaCure is developing innovant drugs capable of treating divers troubles sensoriels. L'entreprise's flagship pipeline, traitement de la sécheresse oculaire 'RCI001,' utilizes a mechanism that suppresses activation inflammatoire through TRPV1 downstream signal modulation. Unlike existing treatments, it demonstrates powerful anti-inflammatoire and effets antioxydants, showing thérapeutique results within 4 weeks along with confirmed increases in production lacrymale. Notamment, it a été reconnue pour overcoming major effets secondaires associated with steroid-based treatments, notamment élévation de la pression intraoculaire, hyperemia, hemorrhage, and burning sensation upon instillation.
RudaCure signed two accord de transfert de technologies with Hanlim Pharmaceutical totaling KRW 20 billion in 2021 and 2022, gaining recognition for RCI001's technical excellence. In July 2025, l'entreprise achieved FDA Phase 2 IND (nouveau médicament en investigation) approval, with national essais cliniques de Phase 2 planned for 2026. L'entreprise is also expanding into the pharmaceutique vétérinaire market with a KRW 50 billion contrat with a French global médicament vétérinaire developer.
The chronic traitement de la douleur 'RCI002' is a dual-target analgésique non narcotique that simultaneously targets TRPV1 and MOR (Mu-Opioid Receptor). In études précliniques, it demonstrated prolonged efficacy at concentrations 650 times lower than existing treatments with aucun effet secondaire, and is applicable to divers troubles sensoriels notamment douleur neuropathique, chemotherapy-induced pain, and diabetic pain without the addiction risk of analgésiques narcotiques.
Behind RudaCure's selection as an remarquable company is not only its excellent technology but also its stable organizational culture. L'entreprise has fostered an environment where employés grow together sur la base de its 3C core values: Creativity, Collaboration, and Challenge.
L'entreprise offers divers financial incentives notamment stock options, performance bonuses, and long-service allowances, along with flexible work culture tels que liberal use of annual leave and casual dress code. It also actively supports employé self-development through education expense subsidies and professional skill enhancement training. En conséquence, l'entreprise maintains a low turnover rate, and employés are moving toward the goal of développement de médicaments innovants as One Team, backed by high workplace satisfaction and pride.
RudaCure has consistently been recognized for its organizational excellence, being selected as a Talent-Nurturing SME, Outstanding Job Invention Compensation Company, and Work Innovation Excellence Company in 2022. In 2023, it a été sélectionnée pour le Ministère de Employment and Labor's Strong Small Enterprise program and the Ministère de SMEs and Startups' Startup Leap Package programme de soutien. In 2024, it a été sélectionnée pour le Baby Unicorn 200 Development Program, demonstrating its potentiel de croissance. L'entreprise a levé over KRW 16 billion in total investissement through Series A (KRW 6 billion) and Series B (KRW 10 billion), strengthening its R&D capabilities. Through accord de transfert de technologies with Hanlim Pharmaceutical and a French pharmaceutique vétérinaire developer, l'entreprise a signé contrats totaling over KRW 70 billion, and is actuellement discussing transfert de technologie for traitement de la douleur RCI002 with multiple overseas companies. Continuous revenue growth and transfert de technologie achievements further enhance de l'entreprise development potential.
le PDG Yongho Kim of RudaCure is an expert who has conducted over 15 years of basic medical research on pain and troubles sensoriels as a professor at Gachon University College of Medicine. L'entreprise continues to secure globally compétitif talent, notamment the recruitment of Directeur de recherche Jiyoon Shin to enhance développement de médicaments efficiency using AI.
le PDG Kim a déclaré : "This selection as an Incheon Outstanding Company is a recognition of RudaCure's R&D capabilities and innovant technology," adding, "Sur la base de our proprietary TRPV1 modulation technology plateforme, we will provide more effective and safer treatment options for patients suffering from troubles sensoriels and grow into a globally compétitif pharmaceutique development company."
RudaCure is targeting an IPO by 2027 in the mid-to-long term. To this end, l'entreprise is concentrating all its capabilities on generating R&D achievements through successful essais cliniques and global transferts de technologie. Through its presence at Incheon Startup Park and its New York office in the US, l'entreprise is building a global cooperation network and laying the foundation for growth into a world-class entreprise pharmaceutique.
With its headquarters in Songdo, Yeonsu-gu, Incheon and its centre de recherche in Gasan, Geumcheon-gu, Seoul, RudaCure contributes to local job creation and economic development while establishing itself as a socially responsible company through the adoption of eco-friendly drug manufacturing technology and sustainable management practices.
